Download PDF
CC BY-NC-ND 4.0 · European Journal of General Dentistry 2012; 1(03): 131-136
DOI: 10.4103/2278-9626.105351
Review Article

Bisphosphonate related osteonecrosis of the jaws: An update

R Anil Kumar
Department of Oral & Maxillofacial Surgery, Institute of Dental Education and Advanced Studies, Gwalior, India
,
Chand Sawhney
1   Department of Orthodontics, Institute of Dental Education and Advanced Studies, Gwalior, India
,
Santosh Kumar
2   Department of Orthodontics and Dentofacial Orthopedics, Manipal College of Dental Sciences, Manipal University, Manipal, Karnataka, India
,
Mohita Dhingra
3   Department of Conservative Dentistry, SGT, Gurgoan, Haryana, India
› Author Affiliations
› Further Information
Also available at
  PDF Download Permissions and Reprints

Abstract

Bisphosphonates (BPs) have been recommended for the use in patients with various bony lesions such as Paget′s disease, hypercalcemia, osteoporosis, and multiple myeloma. Despite the increasing use and various benefits, bisphosphonate related osteonecrosis of the jaw (BRONJ) is a significant complication with significant morbidity. A search of PUBMED journal databases from January 2000 to April 2012 was conducted with the objective of identifying publications regarding BRONJ. Based on the available data current concepts in the diagnosis and management of BRONJ are discussed in this article.

Keywords

Bisphosphonates - jaw - osteonecrosis


Publication History

Article published online:
01 November 2021

© 2012. European Journal of General Dentistry. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Mehrotra B, Fantasia J, Nissel-Horowitz S. Osteonecrosis of the maxilla: An unusual complication of prolonged bisphosphonate therapy. A case report. [Abstract 3194] Proceedings Am Soc Clin Oncol 2003;22:795.
  • 2 Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg 2004;62:527-34.
  • 3 Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J Oral Maxillofac Surg 2003;61:1115-7.
  • 4 Migliorati CA. Bisphosphanates and oral cavity avascular bone necrosis. J Clin Oncol 2003;21:4253-4.
  • 5 Starck WJ, Epker BN. Failure of osseointegrated dental implants after diphosphonate therapy for osteoporosis: A case report. Int J Oral Maxillofac Implants 1995;10:74-8.
  • 6 Zahrowski JJ. Bisphosphonate treatment: An orthodontic concern calling for a proactive approach. Am J Orthod Dentofacial Orthop 2007;131:311-20.
  • 7 Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005;63:1567-75.
  • 8 Tarassoff P, Csermak K. Avascular necrosis of the jaws: Risk factors in metastatic cancer patients. J Oral Maxillofac Surg 2003;61:1238-9.
  • 9 Bone HG, Santora AC. Ten years of alandronate for osteoporosis in post-menopausal women. N Engl J Med 2004;351:191-2.
  • 10 Nussbaum SR, Younger J, Vandepol CJ, Gagel RF, Zubler MA, Chapman R, et al. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: Comparison of 30-, 60-, and 90-mg dosages. Am J Med 1993;95:297-304.
  • 11 Major P, Lortholary A, Hon J, Abdi E, Mills G, Menssen HD, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: A pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 2001;19:558-67.
  • 12 Hortobagyi GN, Theriault RL, Lipton A, Porter L, Blayney D, Sinoff C, et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol 1998;16:2038-44.
  • 13 Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol 1998;16:593-602.
  • 14 Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: A randomized, double-blind, multicenter, comparative trial. Cancer 2003;98:1735-44.
  • 15 Coleman RE. Bisphosphonates: clinical experience. Oncologist 2004;9:14-27.
  • 16 Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004;96:879-82.
  • 17 Rosen LS, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, Krzakowski M, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: A phase III, double-blind, randomized trial-The zoledronic acid lung cancer and other solid tumors study group. J Clin Oncol 2003;21:3150-7.
  • 18 Physicians Desk Reference (Ed 57). Montrole, NJ: Medical Economics; 2003.
  • 19 Delmas PD, Meunier PJ. The management of Paget′s disease of bone. N Engl J Med 1997;336:558-66.
  • 20 Letocha AD, Cintas HL, Troendle JF, Reynolds JC, Cann CE, Chernoff EJ, et al. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement. J Bone Miner Res 2005;20:977-86.
  • 21 Watts NB. Bisphosphonate treatment of osteoporosis. Clin Geriatr Med 2003;19:395-414.
  • 22 Delmas PD. The use of bisphosphonates in the treatment of osteoporosis. Curr Opin Rheumatol 2005;17:462-6.
  • 23 Haderslev KV, Tjellesen L, Sorensen HA, Staun M. Alendronate increases lumbar spine bone mineral density in patients with Crohn′s disease. Gastroenterology 2000;119:639-46.
  • 24 Zein CO, Jorgensen RA, Clarke B, Wenger DE, Keach JC, Angulo P, et al. Alendronate improves bone mineral density in primary biliary cirrhosis: A randomized placebo-controlled trial. Hepatology 2005;42:762-71.
  • 25 Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, et al. Ten years′ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004;350:1189-99.
  • 26 Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg 2004;62:527-34.
  • 27 Hahnecker JA. Novartis "Appendix 9: Dear doctor" Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA precautions added to label of Aredia and Zometa; September 24, 2004.
  • 28 Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007;65:369-76.
  • 29 Madrid C, Sanz M. What impact do systemically administrated bisphosphonates have on oral implant therapy? A systematic review. Clin Oral Implants Res 2009;20:87-95.
  • 30 Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors. J Clin Oncol 2005;23:8580-7.
  • 31 Dimopoulos M, Kastritis E, Moulopoulos LA, Melakopoulos I, Anagnostopoulos A, Gika D, et al. The incidence of osteonecrosis of the jaw in patients with multiple myeloma who receive bisphosphonates depends on the type of bisphosphonate. Blood American Society of Hematology Annual Meeting Abstracts) 2005;106:637.
  • 32 Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B, et al. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws-2009 update. J Oral Maxillofac Surg 2009;67:2-12.
  • 33 Walter C, Al-Nawas B, Grötz KA, Thomas C, Thuroff JW, Zinser V. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. Eur Urol 2008;54:1066-72.
  • 34 Durie GM, Katz M, Crowly J. Osteonecrosis of the jaws and bisphosphonates. N Engl J Med 2005;353:99-100.
  • 35 Badros A, Weikel D, Salama A, Goloubeva O, Schneider A, Rapoport A, et al. Osteonecrosis of the jaw in multiple myeloma patients: Clinical features and risk factors. J Clin Oncol 2006;24:945-52.
  • 36 Rinchuse DJ, Rinchuse DJ, Sosovicka MF, Robison JM, Pendleton R. Orthodontic treatment of patients using bisphosphonates: A report of 2 cases. Am J Orthod Dentofacial Orthop 2007;131:321-6.
  • 37 Ruggiero SL, Fantasia J, Carlson E. Bisphosphonate-related osteonecrosis of the jaw: Background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006;102:433-41.
  • 38 Hoff AO, Toth BB, Altundag K, Guarneri V, Adamus A, Nooka AK, et al. Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy. J Clin Oncol 2006;24:8528. Available from: http://meeting.jco.org/cgi/content/abstract/24/18_suppl/8528 [Last accessed 2012 Aug 15].
  • 39 Sarasquete ME, González M, San Miguel JF, García-Sanz R. Bisphosphonate-related osteonecrosis: Genetic and acquired risk factors. Oral Dis 2009;15:382-7.
  • 40 Yamaguchi K, Oizumi T, Funayama H, Kawamura H, Sugawara S, Endo Y. Osteonecrosis of the jawbones in 2 osteoporosis patients treated with nitrogen-containing bisphosphonates: Osteonecrosis reduction replacing NBP with non-NBP (etidronate) and rationale. J Oral Maxillofac Surg 2010;68:889-97.
  • 41 Wehrhan F, Hyckel P, Ries J, Stockmann P, Nkenke E, Schlegel KA, et al. Expression of Msx-1 is suppressed in bisphosphonate associated osteonecrosis related jaw tissue-etiopathology considerations respecting jaw developmental biology-related unique features. J Transl Med 2010;8:96.
  • 42 Madrid C, Bouferrache K, Abarca M, Jaques B, Broome M. Bisphosphonate-related osteonecrosis of the jaws: How to manage cancer patients. Oral Oncol 2010;46:468-70.
  • 43 Lai JB, Poon CY. A Rational approach to dental management of patients on bisphosphonates. Singapore Dent J 2011;32:1-13.
  • 44 Marx RE, Cillo JE Jr, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: Risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 2007;65:2397-410.
  • 45 Kwon YD, Kim DY, Ohe JY, Yoo JY, Walter C. Correlation between serum C-terminal cross-linking telopeptide of type I collagen and staging of oral bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2009;67:2644-8.
  • 46 Bagan JV, Jiménez Y, Gómez D, Sirera R, Poveda R, Scully C. Collagen telopeptide (serum CTX) and its relationship with the size and number of lesions in osteonecrosis of the jaws in cancer patients on intravenous bisphosphonates. Oral Oncol 2008;44:1088-9.
  • 47 Cheung A, Seeman E. Teriparatide therapy for alendronate-associated osteonecrosis of the jaw. N Engl J Med 2010;363:2473-4.
  • 48 Brozoski MA, Traina AA, Deboni MC, Marques MM, Homem MG. Bisphosphonate-related osteonecrosis of the jaw. Rev Bras Reumatol 2012;52:260-70.
  • 49 Ruggiero SL, Woo SB. Biophosponate-related osteonecrosis of the jaws. Dent Clin North Am 2008;52:111-28.